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Abstract
Background: During the inflammation which occurs following nerve damage, macrophages are recruited to the
site of injury. Phenotypic diversity is a hallmark of the macrophage lineage and includes pro-inflammatory M1 and
anti-inflammatory M2 populations. Our aim in this study was to investigate the ability of polarized M0, M1, and M2
macrophages to secrete opioid peptides and to examine their relative contribution to the modulation of
neuropathic pain.
Methods: Mouse bone marrow-derived cells were cultured as unstimulated M0 macrophages or were stimulated into
an M1 phenotype using lipopolysaccharide and interferon-γ or into an M2 phenotype using interleukin-4. The
macrophage phenotypes were verified using flow cytometry for surface marker analysis and cytokine bead array
for cytokine profile assessment. Opioid peptide levels were measured by radioimmunoassay and enzyme immunoassay.
As a model of neuropathic pain, a chronic constriction injury (CCI) of the sciatic nerve was employed. Polarized M0, M1,
and M2 macrophages (5 × 105 cells) were injected perineurally twice, on days 14 and 15 following CCI or sham surgery.
Mechanical and heat sensitivity were measured using the von Frey and Hargreaves tests, respectively. To track the
injected macrophages, we also transferred fluorescently stained polarized cells and analyzed the surface marker profile
of endogenous and injected cells in the nerves ex vivo.
Results: Compared to M0 and M1 cells, M2 macrophages contained and released higher amounts of opioid peptides,
including Met-enkephalin, dynorphin A (1–17), and β-endorphin. M2 cells transferred perineurally at the nerve injury
site reduced mechanical, but not heat hypersensitivity following the second injection. The analgesic effect was reversed
by the perineurally applied opioid receptor antagonist naloxone methiodide. M2 cells did not affect sensitivity
following sham surgery. Neither M0 nor M1 cells altered mechanical and heat sensitivity in CCI or sham-operated
animals. Tracing the fluorescently labeled M0, M1, and M2 cells ex vivo showed that they remained in the nerve
and preserved their phenotype.
Conclusions: Perineural transplantation of M2 macrophages resulted in opioid-mediated amelioration of neuropathy-
induced mechanical hypersensitivity, while M1 macrophages did not exacerbate pain. Therefore, rather than focusing
on macrophage-induced pain generation, promoting opioid-mediated M2 actions may be more relevant for pain
control.
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Background
Around 7 % of Europeans suffer from chronic neuro-
pathic pain [1]. This is characterized as a spontaneously
occurring, burning pain with increased sensitivity to
mechanical and thermal stimuli [2, 3]. It often develops
following peripheral nerve injury as a result of trauma or
disease such as herpes virus or diabetes mellitus, and
only 40–60 % of sufferers gain relief from treatment [2,
4]. The systemic administration of classical opioids such
as morphine might be an effective treatment in some
neuropathic conditions [5]. The use of these drugs re-
mains controversial, however, due to the high dosage re-
quired and the central side effects, including sedation,
respiratory depression, cognitive impairment, and de-
pendence [6, 7]. The obvious and numerous drawbacks
of the current treatment highlight the need for new,
more effective therapeutic strategies and mechanistic in-
sights into neuropathic pain control. There is evidence
that activation of opioid receptors on peripheral sensory
neurons results in effective analgesia devoid of central
adverse effects. This can be achieved through the injec-
tion of exogenous opioids in small, systemically inactive
doses into peripheral injured tissue or via endogenous
opioid peptides, including Met-enkephalin, dynorphin A
(1-17) (dynorphin), and β-endorphin released from lo-
cally accumulating immune cells [8–11].
During the inflammation which occurs as a result of
nerve injury, macrophages are recruited to the site of
damage [12–14]. Since the leukocyte influx coincides
with pain, earlier studies focused on pro-nociceptive ac-
tions of macrophages. Strategies based on general deple-
tion of these cells resulted in either complete blockade,
moderate reduction, or no changes in neuropathy-
induced hypersensitivity [15–18]. Importantly, macro-
phages are characterized by phenotypic diversity, includ-
ing pro-inflammatory M1 and anti-inflammatory M2
populations [19, 20]. In previous studies, the macro-
phage function was modified by using agonists of the
peroxisome proliferator-activated receptor-γ (PPAR-γ),
which promote the polarization toward the M2 pheno-
type [20, 21]. Application of a PPAR-γ agonist into in-
cised paws increased M2 macrophage numbers and
mRNA levels of their markers, including the anti-
inflammatory cytokine interleukin-10 (IL-10), which
was associated with the attenuation of postoperative
pain. This analgesic effect was mimicked by a local
transfer of PPAR-γ agonist-treated peritoneal macro-
phages [22]. Additionally, PPAR-γ or toll-like receptor
4 activation in inflamed paws elevated nociceptive
thresholds, which was reversed by local application of
an opioid receptor antagonist, indicating the involve-
ment of endogenous opioid peptides in the carrageenan
or complete Freund’s adjuvant (CFA) inflammatory
pain models [23–25].
The role of polarized macrophages in neuropathic pain
has not been as extensively studied. Injured nerves fol-
lowing partial sciatic nerve ligation were found to be in-
filtrated by M1 and M2 macrophages [26], and
perineural transplantation of the PPAR-γ agonist-treated
macrophages attenuated neuropathy-induced mechanical
hypersensitivity [27]. Another study found that injection
of IL-4 at the nerve injury site shifted the macrophage
phenotype to the M2 anti-inflammatory state, which was
associated with decreased mRNA levels of pro-
inflammatory cytokines and elevated mRNA levels of
anti-inflammatory cytokines, and correlated with ameli-
oration of tactile and thermal hypersensitivity [28]. To-
gether, studies examining the role of phenotypically
different macrophage populations in neuropathy are
sparse and exclusively focused on the actions of
macrophage-derived cytokines. Notably, immune cells
accumulating at damaged nerves also contain opioid
peptides, which upon release activate local neuronal opi-
oid receptors and attenuate neuropathy-induced hyper-
sensitivity in animal models [29–32]. However, the
potential role of opioid peptides derived from different
macrophage populations in neuropathy has so far not
been assessed.
In this study, we investigated the relative contribution
of M0, M1, and M2 macrophages to the modulation of
neuropathic pain using an adoptive transfer strategy, in
a chronic constriction injury (CCI) mouse model. To
this end, we cultured bone marrow-derived macrophages
from mice, inducing a pro-inflammatory M1 phenotype
using lipopolysaccharide (LPS) and interferon-γ (IFN-γ),
and an anti-inflammatory M2 phenotype using IL-4. The
unstimulated M0 phenotype represented a low activation
state. Surface marker analysis by flow cytometry and
cytokine release by cytokine bead array (CBA) were used
to distinguish activation phenotypes. The opioid peptide
content and release were measured using radioimmuno-
assay (RIA) and enzyme immunoassay (EIA). Finally, the
relevance of polarized macrophages in modulation of
mechanical and heat sensitivity in vivo was examined
using von Frey and Hargreaves tests, respectively.
Methods
Animals
Experiments were approved by the State animal care
committee (Landesamt für Gesundheit und Soziales,
Berlin, Germany) and were performed according to the
Guide for the Care and Use of Laboratory Animals
adopted by the U.S. National Institutes of Health and
the ARRIVE guidelines [33]. Male C57BL/6J mice (22–
30 g, 6–13 weeks old; Janvier Laboratories, France; bred
at the Charité-Campus Benjamin Franklin, Berlin,
Germany) were kept in groups of three to five per cage,
with free access to food and water, in environmentally
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controlled conditions (12 h light/dark schedule, light on
at 0700 h; 22 ± 0.5 °C; humidity 60–65 %). Animals were
randomly placed in cages by an animal caretaker who
was not involved in the study. In vivo experiments were
performed by an experimenter blinded to the treat-
ments. Macrophages and substances were prepared in
separate, coded vials by a colleague not involved in in
vivo testing. The codes were broken after completion of
the experiment. After completion of in vivo experiments
and for tissue collection for ex vivo experiments, animals
were killed with isoflurane-overdose (AbbVie). All efforts
were made to minimize animal suffering and to reduce
the number of animals used.
Culture and polarization of bone marrow-derived
macrophages
Bone marrow-derived cells were isolated and cultured as
previously described [34]. In summary, mice were killed
by isoflurane overdose and the femurs and tibias were re-
moved, keeping the femoral head and femur intact, and
cutting off the paw bones below the distal end of the tibia.
Any muscle connected to the bone was carefully removed.
Bones were stored in sterile Hanks’ balanced salt solution
(HBSS) on ice until all bones had been collected. After
cutting through the epiphysis at both ends of the femur
and tibia, sterile HBSS was slowly flushed through the
bone using a 23-G needle and 5-ml syringe, and the con-
tent was collected in a sterile 15-ml polypropylene tube.
Cells were dissociated by briefly passing them through the
syringe, followed by straining using a 70-μm cell strainer.
After centrifugation (4 °C, 7 min at 500g), red blood cells
were lysed by adding 1 ml erythrocyte lysis buffer (QIA-
GEN). After 1–2 min, HBSS (20 ml) was added, the sus-
pension was centrifuged as before, and the supernatant
was removed. Cells were washed in complete Dulbecco’s
modified Eagle medium (DMEM; 20 ml) and again centri-
fuged. After removal of the supernatant, cells were plated
in a 10-cm dish with macrophage colony-stimulating fac-
tor (MCSF; 10 ng/ml; PeproTech) to allow differentiation
of bone marrow cells to macrophages. After 2 days, 5 ml
of media was exchanged from each dish with MCSF
(10 ng/ml). After 6 days, 5 ml of media was exchanged
from each dish without an addition of MCSF. For
polarization of cells to an M2 phenotype, cells were stimu-
lated with IL-4 (20 ng/ml; BD Biosciences) on day 6 for
48 h. For the M1 phenotype, cells were stimulated on day
7 with LPS (100 ng/ml; InvioGen) and IFN-γ (20 ng/ml;
PeproTech) for 24 h. The M0 phenotype represents un-
stimulated cells and were therefore only subjected to the
media change on day 6 [35–37].
Flow cytometry analysis of cell surface markers
To determine the expression of surface markers indicat-
ing macrophage polarization status, cultured bone
marrow macrophages were first labeled with LIVE/
DEAD® fixable aqua dead cell stain kit, for 30 min on
ice, according to the manufacturer’s instructions (Ther-
moFisher Scientific), to exclude dead cells. Cells were
then washed with ice-cold FACS buffer (0.5 % BSA/
PBS), followed by centrifugation and removal of the
supernatant. Cells were then stained for 20 min on ice
with anti-mouse F4/80-eFluor 450 antibody (0.2 μg/
100 μl; eBioscience) as a general marker of macrophages,
anti-mouse major histocompatibility complex II (MHC
II)-PE-Cy7 antibody (0.1 μg/100 μl; eBioscience) as a
marker of M1 macrophages, and mouse anti-rat cluster
of differentiation 163 (CD163)-Alexa 647 antibody
(1 μg/100 μl; AbD Serotec) as a marker of M2 macro-
phages. All antibodies were prepared in FACS buffer.
The staining specificity of antibodies was tested by using
fluorescence minus one (FMO) controls [38]. The per-
centages of positively stained cells determined over
10,000 events were analyzed using FACS Canto II (BD
Biosciences), and fluorescence intensity was expressed in
arbitrary units on a logarithmic scale and analyzed using
FlowJo software (version 10.1r5; TreeStar, Inc.) [39].
Measurement of cytokine levels
Following polarization, macrophages were washed and
seeded in 24-well plates at 2 × 105 cells per well in
500 μl complete DMEM. Approximately 18 h after seed-
ing, media was collected and frozen at −20 °C for ana-
lysis of released cytokines. The concentration of
cytokines was measured using CBA (BD Biosciences),
allowing precise analysis of six cytokines, including IL-6,
IL-10, IL-12p70, monocyte chemoattractant protein-1
(MCP-1), IFN-γ, and tumor necrosis factor-α (TNF-α),
as per manufacturer’s instructions. CBA samples were
run on a FACS Canto II cytometer (BD Biosciences).
Data were analyzed using FCAP-array software (version
3.1; BD Biosciences) to convert fluorescent intensity
values to concentrations using a 10-point standard curve
(0–5000 pg/ml) as described previously [40].
Measurement of opioid peptide levels
Following polarization, macrophages were washed and
seeded at 5 × 105 cells per well in a 24-well plate with
650 μl complete DMEM. Approximately 18 h after seed-
ing, media was removed and frozen at −20 °C for later
analysis of secreted levels of opioid peptides, Met-
enkephalin, dynorphin, and β-endorphin. To measure the
intracellular opioid peptide content, the cells were scraped
from each well, resuspended in RPMI buffer, and lysed by
a freezing/thawing procedure (8 min at −80 °C and 1 min
at 50 °C; repeated five times) followed by sonication
(Ultra-Turrax T8; IKA Labortechnik) [29].
Immunoreactivities of Met-enkephalin and dynorphin
were determined using RIA kits (Peninsula Laboratories),
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while those of β-endorphin were assessed using EIA kits
(Phoenix Pharmaceuticals), according to manufacturers’
instructions and previous studies [29, 41]. Briefly, for Met-
enkephalin and dynorphin measurements using RIA, the
samples were thawed and incubated overnight (4 °C) with
anti-Met-enkephalin or anti-dynorphin, respectively. Re-
spective 125I-labeled opioid peptide tracers were then
added and the samples were incubated overnight at 4 °C.
The following day, goat anti-rabbit IgG and normal rabbit
serum were added and the samples were incubated for
90 min at room temperature. RIA buffer was then applied,
samples were centrifuged, and radioactivity levels were
measured in the pellets using a gamma counter (Wallac/
PerkinElmer 1470 Wizard), according to the standard
curve.
For EIA β-endorphin measurements, samples were
thawed and incubated with anti-β-endorphin and bio-
tinylated peptide (2 h), followed by addition of
streptavidin-horseradish peroxidase (1 h). After washing,
tetramethylbenzidine was added (1 h), the reaction was
terminated by application of 2 N HCl (1 h), and the ab-
sorbance was measured at 450 nm (Molecular Devices
Spectra Max), according to the standard curve.
All RIA and EIA samples were measured in duplicates,
in two to three independent assays [29]. In earlier stud-
ies, we verified the specificity of opioid peptide anti-
bodies by testing all three standard opioid peptides
(Met-enkephalin, dynorphin, and β-endorphin) in all
three RIAs and showing that each opioid peptide was
only recognized by its respective antibody [41], and by
showing the absence of opioid peptide immunoreactiv-
ities in immune cells from the corresponding opioid
peptide knockout mice [29].
Chronic constriction injury
CCI was induced in deeply isoflurane-anesthetized mice
by exposing the sciatic nerve at the level of the right
mid-thigh and placing three loose silk ligatures (4/0)
around the nerve with about 1-mm spacing; the ligatures
were tied until they elicited a brief twitch in the respect-
ive hind limb. Sham operation was performed in a simi-
lar manner but without nerve ligation. The wound was
closed with silk sutures [30].
Evaluation of mechanical sensitivity (von Frey test)
Animals were habituated to the test cages daily (one to
two times for 15 min), starting 6 days prior to nocicep-
tive testing; they were individually placed in clear plexi-
glas cubicles located on a stand with anodized mesh
(Model 410; IITC Life Sciences). To assess the sensitiv-
ity, calibrated von Frey filaments in the range of
0.054 mN (0.0056 g) to 42.85 mN (4.37 g) were used
(Stoelting). The filaments were applied until they bowed,
for approximately 3 s, to the plantar surface of hind
paws. The up-down method was used to estimate 50 %
withdrawal thresholds [42].Testing began using a 2.74-
mN (0.28 g) filament. If the animal withdrew the paw,
the preceding weaker filament was applied. In the ab-
sence of withdrawal, the next stronger filament was ap-
plied. The maximum number of applications was 6–9,
and the cutoff was 42.85 mN (4.37 g). The sequence of
paws was alternated between animals to avoid “order”
effects, according to our previous studies [30, 43, 44].
Evaluation of heat sensitivity (Hargreaves test)
Before experiments, mice were habituated as described
for the von Frey test, except they were placed in clear
plexiglas chambers positioned on a stand with a glass
surface (Model 336; IITC Life Sciences). To examine
heat sensitivity, radiant heat was applied to the plantar
surface of hind paws from underneath the glass floor
with a high-intensity projector lamp bulb and paw with-
drawal latency was evaluated using an electronic timer.
The withdrawal latency was defined as the average of
two measurements separated by at least 10 s. The heat
intensity was adjusted to obtain baseline withdrawal la-
tency of about 10–12 s in uninjured paws, and the cutoff
was set at 20 s to avoid tissue damage [44, 45].
Assessment of analgesic effects of polarized macrophages
Freshly prepared polarized M0, M1, or M2 macrophages
(5 × 105 in 30 μl DMEM) were injected perineurally at
the site of nerve injury (CCI site) twice, on days 14 and
15 following CCI. Mechanical and heat sensitivities were
measured just before CCI, and then after CCI on day 14
(before and 1 and 5 h after the first injection), on day 15
(before and 1 and 5 h after the second injection), and
then daily on days 16–19. Control groups were treated
with DMEM (30 μl) only. Analogous experiments were
performed in sham-operated mice. The concentration of
5 × 105 cells was the most effective of 2.5–10 × 105 cells
tested in pilot experiments using M2 macrophages.
To assess the contribution of peripheral (at the CCI
site) opioid receptors to M2 macrophage-induced anal-
gesia, a peripherally restricted opioid receptor antagon-
ist, naloxone methiodide (NLXM; Sigma-Aldrich) was
used. NLXM (10 μg/30 μl 0.9 % NaCl) was injected at
the CCI site 24 h after the second injection of M2 mac-
rophages (i.e., on day 16 after CCI). Mechanical sensitiv-
ity was measured before NLXM injection (on days 14
and 15 after CCI) and after NLXM injection, 15 min and
1–5 h (on day 16 after CCI), and 24 h (on day 17 after
CCI). The control group was treated with 0.9 % NaCl
(30 μl).
For perineural injections, performed under brief iso-
flurane anesthesia, a polyethylene tube was placed 2 mm
from the tip around the needle (attached to a Hamilton
syringe; Sigma-Aldrich) to ensure the same depth of
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needle insertion into the middle of the scar after surger-
ies [29, 30].
Detection of transferred macrophages in injured nerves
To track the cultured macrophages following in vivo
perineural injections, M0, M1, and M2 macrophages
were treated immediately following polarization with
carboxyfluorescein succinimidyl ester (CFSE; 0.5 μM;
Sigma) for 5 min at 37 °C. The cells were then quenched
using DMEM, followed by centrifugation and a further
two washes with DMEM alone [46].
Fluorescently labeled M0, M1, and M2 macrophages
(each at 5 × 105 in 30 μl DMEM) or DMEM alone
(30 μl) were injected at the CCI site on day 14 (for one
injection) or on days 14 and 15 (for two injections) after
CCI, analogously to unlabeled macrophages described
above. Mice were killed 24 h after the first injection and
24 h after the second injection, and injured nerves (ap-
proximately 1-cm long, including the ligation site and
sites distal and proximal to it) were removed. Nerves
were cut into small pieces and collected in a digestive
solution (10 ml RPMI1640 with GlutaMax, 0.5 ml
HEPES, 30 mg collagenase, 10 mg hyaluronidase, and
2 % FBS) for 30 min at 37 °C. Afterward, the tissue was
filtered through a 70-μm pore sieve (BD Biosciences),
washed with RPMI media, and centrifuged and cell pel-
lets were resuspended in RPMI media. The cells were
counted and verified for viability in a Neubauer chamber
(Optik Labor) using the trypan blue exclusion method,
as described previously [29, 30].
For analysis of CFSE labeling, the cells isolated from
nerves were stained with LIVE/DEAD® fixable aqua dead
cell stain kit, anti-mouse CD45-APC-Alexa780 antibody
(0.1 μg/100 μl; eBioscience) to gate out non-
hematopoietic cells and debris, and with antibodies to
macrophage markers, anti-F4/80-eFluor 450, anti-MHC
II-PE-Cy7, and anti-CD163-Alexa 647, as described
above. The CFSE staining was analyzed in the FITC
channel. To determine the absolute cell numbers,
CountBright™ Absolute Counting Beads (ThermoFisher
Scientific) were used. The absolute cell numbers and the
percentage of positively stained cells were determined
over 20,000 events, and the data were analyzed using
FlowJo software, as specified above.
Statistical analyses
Statistical analyses were performed using GraphPad
Prism software (Version 5.02 for Windows; GraphPad
Software Inc.). Data are expressed as means ± SEM.
One-way repeated measures (RM) analysis of variance
(ANOVA) was used to analyze more than two groups
for dependent data, while one-way ANOVA was used to
analyze more than two groups for independent data.
Two-way RM ANOVA was applied to compare two
groups over time (more than two time points). In all
cases, Bonferroni’s multiple comparison test was used as
a post hoc test. An unpaired two-tailed t test was used
to compare two groups for independent data. Differ-
ences were considered significant at values of p < 0.05.
Results
Polarized bone marrow-derived macrophages display sur-
face marker and cytokine profiles for M1 and M2
activation
Figure 1a, b depicts representative flow cytometry dot
blots from M0, M1, and M2 polarized macrophages to
show that the majority of analyzed cells were positive for
the macrophage marker F4/80, demonstrating successful
generation of macrophages from the bone marrow cells.
To distinguish the macrophage phenotypes, we analyzed
the surface markers MHC II and CD163. MHC II is
expressed on antigen presenting cells and is upregulated
during inflammation [47, 48]; it is therefore commonly
used as a marker for the M1 phenotype [49]. CD163 is a
scavenger receptor for the hemoglobin-haptoglobin
complex [50] and is a marker of cells from the
macrophage-monocyte lineage [51]. It has commonly
been used as a marker of M2 activation [52]. The ana-
lysis of CD163 expression revealed that the percentage
of CD163+ M2 cells was significantly higher than both
M0 and M1 cells. Additionally, the percentage of CD163
+ M1 cells was significantly lower compared to M0 cells
(Fig. 1a, c). The analysis of MHC II expression showed
that the percentage of MHC II+ M1 cells was signifi-
cantly higher than that of M0 and M2 cells. There was
also higher percentage of MHC II+ M2 cells compared
to that of M0 cells (Fig. 1b, d). The staining specificity of
CD163 and MHC II antibodies was confirmed by min-
imal CD163 staining (0.24 %) (Fig. 1a) or absence of
MHC II staining (0 %) in FMO controls (Fig. 1b).
Cytokine release profile is another good indicator of
cell polarization, with M1-activated macrophages com-
monly releasing pro-inflammatory cytokines. Accord-
ingly, analysis using CBA showed significantly higher
released levels of MCP-1, TNF-α, IL-6, and IFN-γ from
M1 polarized cells compared to M0 and M2 cells. MCP-
1 was also secreted in higher amounts by M2 versus M0
cells, but there were no differences in the secretion of
TNF-α, IL-6, and IFN-γ between M2 and M0 cells
(Fig. 2a–d). The levels of IL12p70 and of the anti-
inflammatory cytokine IL-10 were below the detection
limit and therefore not shown. Together, the analysis of
cell surface markers and cytokine profile support the
polarization of bone marrow-derived macrophages into
an M1 phenotype expressing MHC II and releasing pro-
inflammatory cytokines and an M2 phenotype express-
ing CD163 and secreting minimal levels of pro-
inflammatory cytokines.
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M2 polarized macrophages contain and release more
opioid peptides than M0 and M1 cells
Since opioid peptides have so far not been compre-
hensively analyzed in macrophage subpopulations, we
measured the content and release of Met-enkephalin,
dynorphin, and β-endorphin from polarized macro-
phages. We found that M2-polarized cells contained
(Fig. 3a) and secreted (Fig. 3b) significantly higher
levels of all three opioid peptides than M1 and M0
macrophages. Additionally, M1 macrophages con-
tained and released significantly lower opioid peptide
levels that M0 cells (Fig. 3a, b).
Adoptive transfer of M2, but not M1 and M0,
macrophages at the injured nerve results in analgesia
To access the effects of polarized macrophages on
neuropathy-induced mechanical and heat hypersensitivity,
we injected 5 × 105 of M0-, M1-, or M2-polarized macro-
phages at the nerve injury site 14 days following CCI. Cells
were injected directly after polarization and were washed
twice to remove residual polarizing agents. In parallel, ex-
cess cells were seeded to analyze cell surface markers and
opioid and cytokine levels (results discussed above).
Mechanical and heat sensitivity were measured using the




Fig. 1 Analysis of surface markers on cultured macrophages following polarization. a Representative dot blots showing cell populations
expressing F4/80 and CD163. The blots represent the CD163 FMO-negative control (far left), M0-polarized cells (second left), M1 cells
(third left), and M2 cells (far right). The percentage of macrophages negative for CD163 (F4/80+CD163−) are shown in top left quadrants,
while macrophages expressing CD163 (F4/80+CD163+) are shown in top right quadrants. b Representative dot blots showing cell populations
expressing F4/80 and MHC II. The blots show the MHC II FMO-negative control (far left), the M0 cells (second left), the M1 cells (third left), and the M2
cells (far right). The percentage of macrophages negative for MHC II (F4/80+MHC II−) are shown in top left quadrants, while macrophages
expressing MHC II (F4/80+MHC II+) are shown in top right quadrants. c Percentage of polarized M0, M1, and M2 macrophages expressing
CD163. d Percentage of polarized M0, M1, and M2 macrophages expressing MHC II. The data were analyzed using flow cytometry and
FlowJo software. In c and d, **p < 0.01, ***p < 0.001 (one-way RM ANOVA, Bonferroni’s test). Data show the mean ± SEM (n = 8 samples
per group)
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Fig. 2 Pro-inflammatory cytokine release profiles of cultured macrophages following polarization. Released levels of MCP-1 (a), TNF-α (b), IL-6 (c),
and IFN-γ (d). The insert in d shows the graph with smaller Y-axis scale since IFN-γ levels were very low; only levels for M1 were above detection
limit. The cytokine concentrations were measured in media using CBA, ~18 h after polarization was completed. *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 3 Opioid peptide content and release from cultured macrophages following polarization. Intracellular content (a) and extracellular, released
levels (b) of Met-enkephalin, dynorphin, and β-endorphin. Opioid peptide levels were measured by RIA (Met-enkephalin and dynorphin) or EIA
(β-endorphin), ~18 h after polarization was completed. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way RM ANOVA, Bonferroni’s test). Data show the
mean ± SEM (n = 8 samples per group)
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24 h after injection. We found that up to 24 h following the
first injection, none of the injected macrophage populations
had an effect on mechanical hypersensitivity (Fig. 4a). We
then injected polarized cells (5 × 105) a second time, follow-
ing the 24-h measurement after the first injection (i.e., on
day 15 after CCI). We found that the second M2 cell injec-
tion elevated mechanical thresholds 24 h later (Fig. 4a).
This analgesic effect was maintained for at least 29 h (Fig. 5)
and resolved 48 h after the second injection (i.e., on day 17
after CCI) (Figs. 4a and 5). The application of M0 and M1
cells did not significantly alter the CCI-induced mechanical
hypersensitivity (Fig. 4a). None of the macrophage popula-
tions modified CCI-induced heat hypersensitivity (Fig. 4b)
or mechanical thresholds (Fig. 4c) and heat latencies
(Fig. 4d) in sham-operated animals.
M2 macrophage-induced analgesia is mediated by opioids
Since M2 macrophages secreted opioid peptides in vitro
(Fig. 3), we next asked whether opioids contribute to the
M2-mediated amelioration of mechanical hypersensitiv-
ity in vivo. To determine this, we used NLXM, a periph-
erally restricted opioid receptor antagonist. NLXM
(10 μg) was injected at the CCI site, 24 h after the sec-
ond injection of M2-polarized macrophages. We found
that the M2 macrophage-induced analgesic effect was
abolished 15 min after injection of NLXM. The M2 cell
analgesic effect recovered 1 h after NLXM injection,
consistent with a relatively short duration of action of
NLXM (Fig. 5). These data demonstrate that the anal-
gesia following perineural M2 macrophage injection was
mediated by local opioid receptors.
Fluorescent tracking of transferred polarized macrophages
shows that they remain at the injured nerve
In order to determine whether injected macrophages re-
main at the nerve, we used the fluorescent tracer CFSE
to mark cultured macrophages before injection. Figure 6
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Fig. 4 Effects of polarized macrophages transferred at the nerves on sensitivity following CCI and sham surgery. a, b Effects of M0, M1, and M2
macrophages on mechanical (a) and heat hypersensitivity (b) following CCI. c, d Effects of M0, M1, and M2 macrophages on mechanical (c) and
heat sensitivity (d) following sham surgery. Macrophages or control DMEM were injected at the site of CCI or sham surgery on days 14 and 15
following surgeries (indicated by arrows). Mechanical and heat sensitivity were measured using von Frey filaments and Hargreaves test,
respectively. ***p < 0.001 vs. control (DMEM); two-way RM ANOVA, Bonferroni’s test. Data show the mean ± SEM (n = 9 animals per group)
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using flow cytometry 24 h after CFSE staining. Around
98 % of cells from all treatments were CFSE positive,
with no significant differences between M0, M1, and M2
cells. Live/dead staining did not show any difference in
viability compared to unstained cells (data not shown).
CFSE-stained M0, M1, and M2 cells (5 × 105 cells
each) or control DMEM only were then injected at the
injury site on day 14 (one injection) or on days 14 and
15 (two injections) after CCI. Mice were killed 24 h after
the first injection and 24 h after the second injection,
and cell numbers from the nerves were verified by quan-
tification of CD45+ cells and F4/80+ macrophages using
flow cytometry. Figure 7a shows representative dot blots,
demonstrating CD45+ cells after the first injection of
DMEM or M2 macrophages, with little CD45 staining in
the CD45 FMO negative control. Quantitative analysis
revealed significantly higher numbers of CD45+ cells
after the first injection of M0 and M1, but not M2 cells,
compared to DMEM control which represents endogen-
ous CD45+ cells (Fig. 7b). After the second injection, the
number of CD45+ cells significantly increased following
injection of all three M0, M1, and M2 populations com-
pared to the DMEM group, but there was significantly
fewer CD45+ cells in animals receiving M2 vs. M0 cells
(Fig. 7c). The number of CD45+ cells from the M0-, M1-
, and M2-injected animals was significantly higher after
the second injection compared to the number following
the first injection. The CD45+ cell numbers in control
groups only receiving DMEM did not differ between the
two time points (Fig. 7b, c).
Next, we analyzed the F4/80+ macrophages in the
nerves. As we were able to show that the vast majority
of CFSE-stained cultured macrophages remained CFSE
positive 24 h after staining (Fig. 6), we were able to con-
clude that F4/80+CFSE+ cells were injected macro-
phages, while F4/80+CFSE- cells were endogenous
macrophages. This can be seen in the representative dot
blots in Fig. 8 showing that after the first perineural in-
jection of DMEM alone, there was virtually no staining
for injected macrophages (F4/80+CFSE+; Fig. 8a, top
right quadrant), while there was a clear F4/80+CFSE−
population of endogenous macrophages (Fig. 8a, top left
quadrant). In contrast, after the first perineural injection
of CFSE-labeled M2 macrophages, there was a clear F4/
80+CFSE− endogenous population (Fig. 8b, top left quad-
rant) and F4/80+CFSE+ injected population (Fig. 8b, top
right quadrant) of macrophages.
The quantitative analysis of endogenous macrophages
(F4/80+CFSE−) isolated from the nerves revealed that their
absolute numbers were not significantly altered by peri-
neurally injected M0, M1, and M2 cells as compared to
the control DMEM-treated group following the first injec-
tion (Fig. 8c). After the second injection, the numbers of
endogenous macrophages were also unaltered by the
transfer of M0 and M2 cells. The second M1 cell injection
resulted in a significant, but very small increase in the
number of endogenous macrophages (Fig. 8d). Thus, the
endogenous macrophage counts were not substantially
changed by injection of polarized macrophages.
Analysis of injected macrophages (F4/80+CFSE+) iso-
lated from the nerves showed that following the first in-
jection, the absolute numbers of M0 and M1, but not
M2 cells, were significantly increased compared to the
DMEM-injected group (Fig. 8e). After the second injec-
tion, the injected macrophage numbers were signifi-
cantly elevated in all M0-, M1-, and M2-treated groups
compared to the DMEM-injected group. There were






















17 d  CCI
5h3h2h 15
min Time after NLXM
15 d 16 d 





M2 + NLXM (10μg)
 0 24h
###
### ### ### ###
###
###
### ### ### ###
###
###
Fig. 5 Contribution of peripheral opioid receptors to M2 macrophage-
mediated analgesia in neuropathy-induced mechanical hypersensitivity.
M2 macrophages were injected on days 14 and 15 following CCI, and
opioid receptor antagonist NLXM was applied on day 16 after CCI (i.e.,
24 h after the second injection of macrophages). All injections (indicated
by arrows) were performed at the CCI site, and the effects were assessed
using von Frey filaments. ***p< 0.001 vs. vehicle; ###p< 0.001 vs. baseline
measured 14 days after CCI (two-way RM ANOVA, Bonferroni’s test). Data
















Fig. 6 CFSE labeling of cultured macrophages following polarization.
CFSE (0.5 μM) was added to cells immediately after polarization and
CFSE staining was measured ~24 h later using flow cytometry. p > 0.05
(one-way RM ANOVA). Data show the mean ± SEM (n = 8 samples
per group)
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and M1-treated groups compared to the M2-treated
group (Fig. 8f ). Additionally, the numbers of injected
macrophages were significantly higher after the second
compared to the first injection of M0, M1, and M2 cells
(Fig. 8e, f ). Together, the perineurally injected polarized
macrophages could be detected, particularly after the
second injection, with more M0 and M1 than M2 cells
remaining in the injured nerves.
Injected macrophages modify CD163 and MHC II expression
in endogenous macrophages in the injured nerve
CFSE staining of injected cells and flow cytometry also
allowed us to determine the phenotype of endogenous
macrophages using CD163 and MHC II surface marker
analysis. We did not find significant differences in the
percentage of endogenous macrophages (F4/80+CFSE−)
expressing CD163 after the first injection of polarized M0,
M1, or M2 cells in injured nerves (Fig. 9a). After the sec-
ond injection, however, there was a significant reduction
in the percentage of CD163+ endogenous macrophages in
M0-, M1-, and M2-injected animals compared to DMEM-
injected animals (Fig. 9b). Additionally, the percentage of
CD163+ endogenous macrophages following the second
injection of M0 and M1 cells was significantly lower than
after the first injection (Fig. 9a, b).
The percentage of endogenous macrophages (F4/80
+CFSE-) expressing MHC II was not significantly altered
after the first injection of any polarized cells (Fig. 9c).
However, there was a significant increase in the percent-
age of MHC II+ endogenous macrophages following the
second injection of M1 cells compared to the DMEM-
and M0-injected groups (Fig. 9d). Also, the percentage
of MHC II+ endogenous macrophages following the sec-
ond injection of M0 and M2 cells was significantly lower
than following the first injection (Fig. 9c, d). These data
indicate that the second injection of M0-, M1-, and M2-
polarized cells decreased the CD163+ population of
endogenous macrophages, while M1-injected cells add-
itionally enhanced the MHC II+ population of endogenous
macrophages.
Injected macrophages maintain their activation
phenotype in the injured nerve
Perineurally injected CFSE-stained M0, M1, and M2 cells
were analyzed as above for CD163 and MHC II expression
following isolation from the nerve. The CD163 expression
a
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Fig. 7 Quantification of CD45+ cells in injured nerves following perineural transfer of CFSE-labeled polarized macrophages. a Representative dot
blots of CD45 staining: (left panel) CD45 FMO-negative control; (middle panel) CD45+ cells after one injection of DMEM only; (right panel) CD45+
cells following one injection of M2 macrophages. b Total number of CD45+ cells per nerve after one injection of DMEM only or CFSE-labeled M0,
M1, and M2 cells. c Total number of CD45+ cells per nerve after two injections of DMEM only or CFSE-labeled M0, M1, and M2 cells. In all experiments,
DMEM- or CFSE-labeled macrophages were injected at the injury site on day 14 (one injection) or on days 14 and 15 (two injections) after CCI. Animals
were killed 24 h after the first injection and 24 h after the second injection, and cells from the nerves were analyzed using flow cytometry and FlowJo
software. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA, Bonferroni’s test); ##p < 0.01; ###p < 0.001 compared to same treatment 24 h after the first
injection (unpaired t test). Data show the mean ± SEM (n = 6 animals per group)
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of injected macrophages (F4/80+CFSE+) after the first injec-
tion showed a similar expression profile to cultured macro-
phages not stained with CFSE (Fig. 1c), with a significantly
higher percentage of CD163+ M0 and M2 cells vs. M1 cells
(Fig. 10a). This difference was more striking after the sec-
ond injection when there was also a significantly higher
percentage of CD163+ M2 vs. M0 cells (Fig. 10b). There
was also slightly higher percentage of CD163+ M2 cells fol-
lowing the second than the first injection (Fig. 10a, b).
The MHC II expression of injected CFSE-stained
macrophages (F4/80+CFSE+) was also comparable to
cultured macrophages not stained with CFSE (Fig. 1d),
with a significantly higher percentage of MHC II+ M1
vs. M0 and M2 cells, and of MHC II+ M2 vs. M0
cells, both after the first (Fig. 10c) and second
(Fig. 10d) injections. The percentage of MHC II+ M0
cells was slightly lower following the second than the
first injection (Fig. 10c, d).
a
1 injection of macrophages 2 injections of macrophagesc
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Fig. 8 Quantification of endogenous and injected macrophages in injured nerves following perineural transfer of CFSE-labeled polarized macro-
phages. a Representative dot blot of F4/80 and CFSE staining after one injection of DMEM only, showing endogenous macrophages (F4/80+CFSE
−) in the top left quadrant, and the lack of injected macrophages (F4/80+CFSE+) in the top right quadrant. b Representative dot blot of F4/80 and
CFSE staining after one injection of CFSE-labeled M2 cells, showing endogenous macrophages (F4/80+CFSE−) in the top left quadrant and injected
macrophages (F4/80+CFSE+) in the top right quadrant. c Total number of endogenous macrophages (F4/80+CFSE−) after one injection of DMEM
alone or CFSE-labeled M0, M1, and M2 cells. d Total number of endogenous macrophages (F4/80+CFSE−) after two injections of DMEM alone or
CFSE-labeled M0, M1, and M2 cells. e Total number of injected macrophages (F4/80+CFSE+) after one injection of DMEM alone or CFSE-labeled
M0, M1, and M2 cells. f Total number of injected macrophages (F4/80+CFSE+) after two injections of DMEM alone or CFSE-labeled M0, M1, and
M2 cells. In all experiments, DMEM- or CFSE-labeled macrophages were injected at the injury site on day 14 (one injection) or on days 14 and 15
(two injections) after CCI. Animals were killed 24 h after the first injection and 24 h after the second injection, and cells from the nerves were
analyzed using flow cytometry and FlowJo software. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA, Bonferroni’s test); ##p < 0.01, ###p < 0.001
compared to the same treatment 24 h after the first injection (unpaired t test). Data show the mean ± SEM (n = 6 animals per group)
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Discussion
We have shown here that the anti-inflammatory M2-
polarized macrophages contain and secrete higher levels
of opioid peptides, including Met-enkephalin, dynorphin,
and β-endorphin, compared to pro-inflammatory M1
and unstimulated M0 macrophages in vitro. When
transferred to the nerve injury site, M2 macrophages,
but not M1 and M0 cells, reduced neuropathy-induced
tactile hypersensitivity in vivo. The M2 macrophage-
induced analgesia was mediated by opioids at the dam-
aged nerves since it was blocked by a local injection of
the opioid receptor antagonist naloxone methiodide.
None of the injected macrophages affected the sensitivity
in sham-operated animals.
Macrophages undergo a process of activation upon dis-
ease or injury. The widely described M1/M2 classification
vastly simplifies the complexity of in vivo pathological
conditions, which often involve a spectrum of macrophage
activation states [19, 20, 53]. Nevertheless, despite these
limitations, the M1/M2 model provides useful conceptual
insights into studying macrophage phenotype-dependent
processes [20]. Indeed, polarization using LPS and IFN-γ
for M1 and IL-4 for M2 macrophages are established
methods and have been successfully employed in many
studies [19, 35–37, 54]. Our flow cytometry data, which
indicate a higher percentage of MHC II+ cells in the M1-
polarized population and the predominance of CD163+
cells in M2 population, are in line with previous studies
[47, 55–57]. Similarly, higher levels of pro-inflammatory
cytokines (MCP-1, TNF-α, IL-6, IFN-γ) secreted by M1
than by M2-polarized macrophages are in agreement
with earlier reports [54, 57–59]. The M2 phenotype
has also been characterized by the production of anti-
inflammatory cytokines; however, in our conditions, the
extracellular levels of IL-10 were below detection limit. In
fact, the published data on the IL-10 secretion are incon-
sistent. Some studies reported elevated levels of IL-10 re-
leased by M2 vs. M0 and M1 cells using IL-4 as the M2
polarizing agent [54], while other authors specifically
modified polarizing protocols using a combination of IL-4,
IL-10, and transforming growth factor-β, or by adding
LPS (which typically is used as M1 polarizing agent) to
achieve enhanced IL-10 production by M2 cells [60, 61].
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Fig. 9 Analysis of CD163 and MHC II expression in endogenous macrophages in injured nerves following perineural transfer of CFSE-labeled
polarized macrophages. Endogenous macrophages were identified as F4/80+CFSE− cells. a Percentage of endogenous macrophages expressing
CD163 following one injection of DMEM only or CFSE-labeled M0, M1, and M2 cells. b Percentage of endogenous macrophages expressing
CD163 following two injections of DMEM only or CFSE-labeled M0, M1, and M2 cells. c Percentage of endogenous macrophages expressing MHC
II following one injection of DMEM only or CFSE-labeled M0, M1, and M2 cells. d Percentage of endogenous macrophages expressing MHC II
following two injections of DMEM only or CFSE-labeled M0, M1, and M2 cells. In all experiments, DMEM- or CFSE-labeled macrophages were
injected at the injury site on day 14 (one injection) or on days 14 and 15 (two injections) after CCI. Animals were killed 24 h after the first injection
and 24 h after the second injection, and cells from the nerves were analyzed using flow cytometry and FlowJo software. *p < 0.05, **p < 0.01,
***p < 0.001 (one-way ANOVA, Bonferroni’s test); #p < 0.05, ##p < 0.01 compared to the same treatment 24 h after the first injection (unpaired
t test). Data show the mean ± SEM (n = 6 animals per group)
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by IL-4-polarized M2 macrophages were also reported
[35, 57]. Thus, it appears that using IL-10 as a marker of
macrophage phenotype might be challenging since its
measurements can be differentially influenced by meth-
odological factors [62]. Nevertheless, our analysis of the
CD163 and MHC II expression and pro-inflammatory
cytokine profile is clearly consistent with the M1/M2
polarization status reported in the literature.
It is interesting that M2 macrophages contained and se-
creted substantially higher levels of the opioid peptides
Met-enkephalin, dynorphin, and β-endorphin than M0
and M1 macrophages. The M2 cells contained up to 1.5-
fold and released up to 1.8-fold higher opioid levels than
M0 cells. The differences were even greater when compar-
ing M2 with M1 cells: M2 cells contained up to 5.8-fold
more and released up to 3.6-fold higher opioid levels than
M1 cells. Importantly, these effects are of relevance in vivo
because the transfer of M2 macrophages at the injured
nerve diminished CCI-induced mechanical hypersensitiv-
ity. This analgesia was dependent on opioids, as demon-
strated by its complete blockade by the opioid receptor
antagonist naloxone methiodide. These actions were spe-
cific to neuropathic pain since M2 macrophages were inef-
fective following application at the sham-operated nerves.
Although some improvement of neuropathic pain by M0
cells could be anticipated, the lower capacity to release
opioids might account for their ineffectiveness. It is per-
haps more surprising that M1 macrophages did not en-
hance mechanical or heat sensitivity, despite substantially
lower released amounts of opioid peptides and higher
levels of pro-inflammatory cytokines compared to M0 and
M2 cells.
In order to therefore gain greater insight into the char-
acteristics of the polarized macrophages transferred peri-
neurally, we labeled them using CFSE as a fluorescent
marker before injection and carried out flow cytometry
analysis of all cells isolated from injured nerves ex vivo.
The CFSE labeling enabled us to distinguish injected
(CFSE+) from endogenous (CFSE−) macrophages. We
examined the cells 24 h after the first injection and 24 h
after the second injection, according to in vivo pain/an-
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Fig. 10 Analysis of CD163 and MHC II expression in perineurally injected CFSE-labeled polarized macrophages in injured nerves. Injected macrophages
were identified as F4/80+CFSE+ cells. a Percentage of injected macrophages expressing CD163 following one injection of DMEM only or CFSE-labeled
M0, M1, and M2 cells. b Percentage of injected macrophages expressing CD163 following one injections of DMEM only or CFSE-labeled M0, M1, and
M2 cells. c Percentage of injected macrophages expressing MHC II following one injection of DMEM only or CFSE-labeled M0, M1, and M2
cells. d Percentage of injected macrophages expressing MHC II following two injections of DMEM only or CFSE-labeled M0, M1, and M2 cells.
In all experiments, DMEM medium or CFSE-labeled macrophages were injected at the injury site on day 14 (one injection) or on days 14 and
15 (two injections) after CCI. Animals were killed 24 h after the first injection and 24 h after the second injection, and cells from the nerves
were analyzed using flow cytometry and FlowJo software. **p < 0.01, ***p < 0.001 (one-way ANOVA, Bonferroni’s test); #p < 0.05 compared to
the same treatment 24 h after the first injection (unpaired t test). Data show the mean ± SEM (n = 6 animals per group)
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injected polarized macrophages could be detected in the
nerve. Thus, the total number of injected macrophages
(F4/80+CFSE+) was significantly increased particularly after
the second injection of M0, M1, and M2 cells compared to
DMEM application, while the number of endogenous
macrophages (F4/80+CFSE−) was not substantially altered
across the treatments. This finding also suggests that the
equivalent increase in the total number of all leukocytes
(CD45+ cells) in the nerve was brought about by the
injected macrophages. However, the numbers of injected
cells isolated from nerves were lower than expected, since
we injected 5 × 105 macrophages twice, but found around
5–6 × 105 of M0 and M1 cells and about 4 × 105 of M2 cells
after the second injection. This might be related to tech-
nical reasons since isolation of cells from the nerve 15 and
16 days following CCI is difficult due to a buildup of scar
tissue, which can lead to loss of cells. Another possibility is
that some injected cells were removed/phagocytosed by en-
dogenous cells, and it remains to be clarified why M2 cells
were the most affected. Analysis of the surface marker pro-
file of the injected (CFSE+) M0, M1, and M2 macrophages
following perineural injection showed that these cells
retained their phenotype in vivo; their CD163 and MHC II
expression at both time points following transfer closely re-
sembled the CD163 and MHC II expression profiles seen
in our in vitro culture experiments. However, the pheno-
type of endogenous (CFSE−) macrophages showed some
modifications. Although their CD163 and MHC II expres-
sion profile was not altered following the first injection of
M0, M1, and M2 cells, the second injection of these cells
resulted in a decreased percentage of endogenous macro-
phages expressing CD163 when compared to the DMEM
control. In contrast, the percentage of MHC II+ endogen-
ous macrophages was higher following the second injection
of M1 cells, with no significant alterations induced by
injected M0 and M2 macrophages compared to the DMEM
control. Taken together, these results demonstrate that a
fraction of injected polarized macrophages remain at the in-
jured nerves and generally preserve their original pheno-
type. Additionally, the injected cells seem to have an effect
on the endogenous macrophages, with injected M1 cells
appearing to increase the M1 phenotype of endogenous
macrophages based on the elevated MHC II profile. The
effect on CD163 expression is less clear since it was de-
creased by all injected cells irrespective of their phenotype,
and therefore, the data must be interpreted cautiously as
characterization of macrophage phenotypes in vivo is chal-
lenging and analysis of a broad spectrum of markers would
be required [19, 20, 53].
Recapitulating the findings of our in vitro, in vivo and
ex vivo experiments, it can be concluded that the ability
of M2 cells to produce and secrete the highest levels of
opioid peptides and to preserve their M2 phenotype fol-
lowing perineural transfer underlie their analgesic effects
in vivo. The fact that their numbers ex vivo were lower
than expected may explain the observation that the
neuropathy-induced mechanical hypersensitivity was not
completely reversed to the pre-injury thresholds. There
is also a clear agreement between in vivo and ex vivo ex-
periments showing that two M2 cell injections were
more effective than the single one. The need for multiple
macrophage injections was also demonstrated for recov-
ery from spinal cord injury [63]. Although the numbers
of M0 cells were higher compared to M2 cells following
the perineural transfer, the finding that they released
lower amounts of opioid peptides may account for their
inability to attenuate neuropathy-induced hypersensitiv-
ity. On the other hand, the M1 cells did not enhance
sensitivity following either CCI or sham operation, des-
pite the fact that they secreted the lowest amounts of
opioid peptides and the highest levels of pro-
inflammatory cytokines, preserved their M1 phenotype
following perineural injection and seemed to enhance
the M1 phenotype of endogenous macrophages, and
were detected ex vivo in higher numbers than M2 cells.
Though somewhat unexpected, the findings regarding
M0 and M1 cells are in line with earlier studies suggest-
ing a limited role of macrophages in the generation of
pain. Hence, a general depletion of macrophages often
resulted either in moderate elevations or no changes in
the nociceptive thresholds in models of neuropathic, in-
flammatory, and postoperative pain [15–17, 64, 65]. Fur-
thermore, injection at the nerve or into a hind paw of
non-polarized peritoneal or bone marrow-derived mac-
rophages or of IFN-γ-stimulated macrophages did not
induce pain in sham-operated animals and did not en-
hance hypersensitivity induced by neuropathy or paw in-
cision [17, 22, 27]. Although Abbadie et al. [66] reported
decreased macrophage infiltration and amelioration of
neuropathic pain in mice lacking C-C chemokine receptor
2, indicating pain-promoting actions of macrophages, a re-
cent study found increased numbers of neutrophils as a
compensatory change in these mice [67], which makes the
data interpretation difficult since neutrophils can decrease
hypersensitivity via opioid peptides [68, 69]. In fact, the
paper by Ghasemlou et al. [67] suggested that not pro-
inflammatory monocytes, but subset(s) of CD11+ myeloid
cells (e.g., dendritic, Langerhans, natural killer, and/or
mast cells) may mediate postoperative and inflammatory
hypersensitivity. Together, the role of macrophages, in-
cluding pro-inflammatory M1 cells as drivers of pain
might be smaller than generally assumed, and the investi-
gation of a relative contribution of macrophages vs. other
cells such as fibroblasts, endothelial, and Schwann cells is
warranted [70].
In contrast, our findings highlight the favorable actions
of M2 macrophages in neuropathic pain. In previous
studies, macrophage depletion enhanced pain due to
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impaired actions of opioid peptides or IL-10 in the CFA
and carrageenan inflammatory pain models, respectively
[25, 71]. The analgesic effects of anti-inflammatory cyto-
kines derived from M2 cells in response to a PPAR-γ
agonist or IL-4 application have been suggested by
showing a correlation between the attenuation of pain
and enhanced mRNA levels of IL-10 in postoperative
and neuropathic pain models; the direct contribution of
IL-10, however, has not been examined [22, 27, 28].
Additionally, promoting the anti-inflammatory macro-
phage phenotype in response to PPAR-γ activation re-
sulted in naloxone-reversible attenuation of carrageenan
or CFA-induced inflammatory pain [23, 24]. Thus, accu-
mulating evidence demonstrates the beneficial actions of
macrophages in pain control, and our findings define the
M2 phenotype as the most relevant macrophage source
of opioid peptides to attenuate neuropathy-induced
mechanical hypersensitivity.
Interestingly, in our experiments, M2 macrophages did
not ameliorate heat hypersensitivity resulting from neur-
opathy. Few studies reported attenuation of both mech-
anical and heat hypersensitivity by activation of
macrophage PPAR-γ or toll-like receptor 4 in incisional
and CFA-induced inflammatory pain models [22, 25].
Several other reports, however, found that a phenotypic
shift to M2 in response to a PPAR-γ agonist or mor-
phine did not improve heat, but attenuated mechanical
hypersensitivity following hind paw incision or inflam-
mation induced by carrageenan or CFA [23, 24, 65].
While the reasons for the differences among these stud-
ies and the mechanisms underlying the role of immune
cells in the modulation of different pain modalities re-
main to be elucidated [67], our findings add to those
which suggest that promoting an M2 phenotype might
be particularly beneficial in improving mechanical
hypersensitivity.
Although we focused on analgesic actions of in vitro po-
larized, and in vivo transferred M2 macrophages, the role
of endogenous M2 macrophages should also be addressed.
Our data indicate that endogenous M2 macrophages do
not substantially contribute to the constitutive control of
neuropathic pain. Hence, although endogenous M2 cells
were present in injured nerves (DMEM groups in Fig. 9a,
b), mice experienced substantial mechanical and heat
hypersensitivity following CCI in vivo. Our earlier studies
suggest that endogenous immune cells which accumulate
at the injured nerve do contain opioid peptides, but need
to be stimulated to release them and ameliorate neuro-
pathic pain in animals, for example, by corticotropin-
releasing factor or opioid receptor agonists [11, 14, 29,
30]. These endogenous cells included macrophages, but
with previous approaches, it was not possible to distin-
guish their phenotypes. Thus, it is conceivable that en-
dogenous macrophages need to be activated/polarized
toward M2 phenotype in vivo to exert opioid-mediated
analgesia, which would constitute a separate project.
Conclusions
As we have employed the macrophage transfer as a tool
to delineate their pain-modulating properties, other re-
searches have utilized this strategy as a therapy for ner-
vous system disorders such as spinal cord injury [72, 73].
Since the injection of macrophages might result in their
own [37], or endogenous cell phenotypic changes (this
study), future work will be needed to verify the utility of
the adoptive cell transfer in improving the disease out-
come. Our data suggest that macrophages might be less
relevant to the generation of pain since polarizing these
cells to an M1 pro-inflammatory phenotype did not ex-
acerbate mechanical or heat sensitivity. In fact, our find-
ings emphasize the need to focus on the production of
M2-inducing therapeutics. For the first time, we have
provided robust analysis of opioid peptide content and
release from M0, M1, and M2 macrophages. We have
shown that M2 cells can be manipulated in vitro to pro-
duce an opioid-mediated analgesic effect in neuropathy
in vivo. The next step will be to define the most effective
strategy to promote the opioid-mediated M2 responses
for the better control of pathological pain.
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